A claims data study in Germany

High burden of disease in patients with ANCA-associated vasculitis - A claims data study in Germany

Authors: H. G. Haller, S. von Vietinghoff, P. Spearpoint, A.Deichmann, I. Buchholz, M. P. Schönermark, P. Rutherford, D. Götte, Journal: Der Internist (2021), Date of publication: October 19th, 2021

Background & Objectives:

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group of rare chronic autoimmune diseases characterized by recurrent systemic inflammation provoking multiple morbidities. AAV patients suffer from various organ manifestations and treatment-related severe adverse effects. This retrospective study investigated the concrete burden of AAV disease on patients in Germany.

Methods:

Based on anonymized longitudinal German statutory health insurance (SHI) claims data from the years 2011–2016, a representative cohort of approximately 3 million insured persons was used to identify patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and selected clinical aspects were systematically assessed.

Results:

The most frequent concomitant morbidities of GPA and MPA were renal and respiratory disorders. Severe renal involvement occurred in 11.6% of GPA and 24.3% of MPA patients within 15 quarters of diagnosis. Severe infections developed in one third of AAV patients within the first three quarters post-diagnosis. The annual rate of major relapses was 5–8%. AAV patients with renal impairment or infections showed increased annual mortality rates of 14.4 and 5.6%, respectively.

Conclusion:

Based on this analysis of German health care data, disease-specific assumptions regarding the burden on AAV patients were confirmed and concretized for the German context. AAV patients suffer froma high burden of morbidity, including multiple disease manifestations, relapses, and severe complications due to AAV treatment.

Find the complete publication online on https://link.springer.com/article/10.1007%2Fs00108-021-01181-z

to the top